icrf 198 has been researched along with aclarubicin in 1 studies
| Studies (icrf 198) | Trials (icrf 198) | Recent Studies (post-2010) (icrf 198) | Studies (aclarubicin) | Trials (aclarubicin) | Recent Studies (post-2010) (aclarubicin) |
|---|---|---|---|---|---|
| 24 | 0 | 4 | 826 | 97 | 105 |
| Protein | Taxonomy | icrf 198 (IC50) | aclarubicin (IC50) |
|---|---|---|---|
| 72 kDa type IV collagenase | Homo sapiens (human) | 9.9 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 1.106 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Allan, WP; Creighton, AM; Fattman, CL; Hasinoff, BB; Kuschak, TI; Thampatty, P; Yalowich, JC | 1 |
1 other study(ies) available for icrf 198 and aclarubicin
| Article | Year |
|---|---|
Characterization of a Chinese hamster ovary cell line with acquired resistance to the bisdioxopiperazine dexrazoxane (ICRF-187) catalytic inhibitor of topoisomerase II.
Topics: Aclarubicin; Animals; CHO Cells; Cricetinae; DNA Topoisomerases, Type II; Drug Resistance; Ethylenediamines; Etoposide; Glycine; Mutation; Razoxane; Thiobarbiturates; Topoisomerase II Inhibitors; Verapamil | 1997 |